{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:22:46Z","timestamp":1791958966012,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005897","name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie et de Pathologie Sexuellement Transmissible","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jaad.2020.09.055","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T12:27:22Z","timestamp":1601468842000},"page":"1278-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study"],"prefix":"10.1016","volume":"84","author":[{"given":"Pascal","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Tejedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tetart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne Collas","family":"Cailleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Barrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Arnaud","family":"De Preville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Mion-Mouton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germaine","family":"Gabison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Baricault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine Girardin","family":"Tordeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Xavier","family":"Dore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Bourseau-Quetier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Chamaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chosidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aleth","family":"Richard-Lallemand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Rzeznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Amici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Lair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bechu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Benichou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.09.055_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMcp0806464","article-title":"Seborrheic dermatitis","volume":"360","author":"Naldi","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.09.055_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00128071-200405060-00006","article-title":"Role of antifungal agents in the treatment of seborrheic dermatitis","volume":"5","author":"Gupta","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib3","first-page":"1013","article-title":"Seborrheic dermatitis and dandruff: a comprehensive review","volume":"3","author":"Borda","year":"2015","journal-title":"J Clin Invest Dermatol"},{"issue":"1 pt 2","key":"10.1016\/j.jaad.2020.09.055_bib4","first-page":"115","article-title":"Seborrheic dermatitis: frequent but unknown","volume":"131","author":"Lorette","year":"2004","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.055_bib5","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/archderm.139.12.1614","article-title":"French people and skin diseases: results of a survey using a representative sample","volume":"139","author":"Wolkenstein","year":"2003","journal-title":"Arch Dermatol"},{"issue":"8-9 pt 1","key":"10.1016\/j.jaad.2020.09.055_bib6","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0151-9638(06)70987-5","article-title":"Skin diseases observed in the dermatology departments of three French university teaching hospitals","volume":"133","author":"Lambert","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.055_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1365-2133.2001.04082.x","article-title":"Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry","volume":"144","author":"Faergemann","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.jid.5701017","article-title":"Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects","volume":"128","author":"Tajima","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1046\/j.1523-1747.2001.01321.x","article-title":"The effects of Malassezia yeasts on cytokine production by human keratinocytes","volume":"116","author":"Watanabe","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib10","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0001-7310(07)70111-4","article-title":"Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis","volume":"98","author":"Peyr\u00ed","year":"2007","journal-title":"Acta Dermosifiliogr"},{"key":"10.1016\/j.jaad.2020.09.055_bib11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000068904","article-title":"Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis","volume":"206","author":"Chosidow","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2020.09.055_bib12","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1365-2133.2001.04194.x","article-title":"Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis","volume":"144","author":"Dupuy","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib13","first-page":"646","article-title":"Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial","volume":"5","author":"Elewski","year":"2006","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib14","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1046\/j.1365-2133.2003.05328.x","article-title":"Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: a multicentre, randomized study","volume":"148","author":"Dreno","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib15","first-page":"1001","article-title":"A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions","volume":"6","author":"Elewski","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2008.02.008","article-title":"Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle","volume":"58","author":"Breneman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1067\/mjd.2003.450","article-title":"An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis","volume":"49","author":"Meshkinpour","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib18","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1046\/j.1365-2133.2003.05383.x","article-title":"Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study","volume":"148","author":"Braza","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1517\/13543784.16.8.1267","article-title":"Assigning new roles to topical tacrolimus","volume":"16","author":"Rallis","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2020.09.055_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00128071-200708030-00003","article-title":"The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis","volume":"8","author":"Wollina","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib21","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1468-3083.2006.01923.x","article-title":"An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV","volume":"21","author":"De Moraes","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.055_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2006.11.007","article-title":"Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial\u00a0seborrheic dermatitis","volume":"57","author":"Warshaw","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archderm.142.8.1066","article-title":"Pimecrolimus cream 1% vs hydrocortisone acetate cream 1% in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial","volume":"142","author":"Firooz","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.5021\/ad.2015.27.5.523","article-title":"Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment","volume":"27","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib26","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2020.09.055_bib28","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0151-9638(07)92826-4","article-title":"Stress and seborrheic dermatitis","volume":"134","author":"Misery","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2020.09.055_bib29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12888-020-02520-4","article-title":"Psychometric properties of the perceived stress scale in a community sample of Chinese","volume":"20","author":"Huang","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jaad.2020.09.055_bib30","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1345\/aph.1M278","article-title":"Association between exposure to topical tacrolimus or pimecrolimus and cancers","volume":"43","author":"Hui","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaad.2020.09.055_bib31","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/sj.jid.5700622","article-title":"Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis","volume":"127","author":"Arellano","year":"2007","journal-title":"J Invest Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220326517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:57:07Z","timestamp":1759273027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220326517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0190962220326517"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.055","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.09.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}